USWM, LLC (dba US WorldMeds)

Quick facts

Marketed products

• lofexidine HCl · Addiction Medicine / Substance Use Disorder
  Lofexidine is an alpha-2 adrenergic agonist that reduces noradrenergic hyperactivity in the central nervous system to alleviate opioid withdrawal symptoms.

Phase 3 pipeline

• Open Label Lofexidine HCL · Addiction Medicine / Substance Use Disorder
  Lofexidine is an alpha-2 adrenergic agonist that reduces noradrenergic hyperactivity associated with opioid withdrawal.

Phase 1 pipeline

• Lofexidine-matching sugar pill

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• USWM, LLC (dba US WorldMeds) portfolio CI brief
• USWM, LLC (dba US WorldMeds) pipeline updates RSS